Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh

Vaccine

Volumn 29, Issue 6, 2011, Pages 1347-1354

  Rahman, Kazi Mizanur ^a   Arifeen, Shams El ^a   Zaman, K ^a   Rahman, Mahbubur ^a   Raqib, Rubhana ^a   Yunus, Mohammad ^a   Begum, Nazma ^a   Islam, Md Shaheenul ^a   Sohel, Badrul Munir ^a   Rahman, Muntasirur ^a   Venkatesan, Malabi ^c   Hale, Thomas L ^c   Isenbarger, Daniel W ^c   Sansonetti, Philippe J ^d   Black, Robert E ^b   Baqui, Abdullah H ^b  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d INSTITUT PASTEUR   (France)

Author keywords

Bangladesh; Randomized controlled trial; SC602; Shigella vaccine

Indexed keywords

IMMUNOGLOBULIN G; PLACEBO; SC602 VACCINE; SHIGELLA VACCINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; ARTHRALGIA; ARTICLE; BANGLADESH; CHEMOTHERAPY INDUCED EMESIS; CHILD; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; HEMATOCHEZIA; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALAISE; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SHIGELLA FLEXNERI; SHIGELLOSIS;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ARTHRALGIA; BACTERIAL SHEDDING; BANGLADESH; CHILD; DOUBLE-BLIND METHOD; DYSENTERY, BACILLARY; FEMALE; HUMANS; MALE; PLACEBOS; SHIGELLA FLEXNERI; SHIGELLA VACCINES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 78751578966     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.035     Document Type: Article

References (20)

1. Bennish M.L., Harris J.R., Wojtyniak B.J., Struelens M. Death in shigellosis: incidence and risk factors in hospitalized patients. J Infect Dis 1990, 161(3):500-506.
2. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77(8):651-666.
3. Baqui A.H., Sack R.B., Black R.E., Haider K., Hossain A., Alim A.R., et al. Enteropathogens associated with acute and persistent diarrhea in Bangladeshi children less than 5 years of age. J Infect Dis 1992, 166(4):792-796.
4. von Seidlein L., Kim D.R., Ali M., Lee H., Wang X., Thiem V.D., et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006, 3(9):e353.
5. Sansonetti P.J. Molecular mechanisms of cell and tissue invasion by Shigella flexneri. Infect Agents Dis 1993, 2(4):201-206.
6. Barzu S., Arondel J., Guillot S., Sansonetti P.J., Phalipon A. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602. Infect Immun 1998, 66(1):77-82.
7. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 2004, 72(2):923-930.
8. ICDDRB, Health and Demographic Surveillance System- Matlab: Registration of Demographic Events and Contraceptive Use 1998. Dhaka, Bangladesh; 2000.
9. Sethabutr O., Venkatesan M., Yam S., Pang L., Smoak B., Sang W., et al. Detection of PCR products of the ipaH gene from Shigella and enteroinvasive Escherichia coli by enzyme linked immunosorbent assay. ASTM&H Conference Proceedings 1998.
10. WHO Future needs and directions for Shigella vaccines. Wkly Epidemiol Rec 2006, 81:51-58.
11. Raqib R., Qadri F., SarkEr P., Mia S.M., Sansonnetti P.J., Albert M.J., et al. Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults. Scand J Immunol 2002, 55(4):414-423.
12. Raqib R., Tzipori S., Islam M., Lindberg A. Immune responses to Shigella dysenteriae type 1 and Shigella flexneri lipopolysaccharide and polysaccharide antigens in Bangladeshi patients with shigellosis. Serol Immun Infect Dis 1993, 1:37-45.
13. Sack D.A., Shimko J., Sack R.B., Gomes J.G., MacLeod K., O'Sullivan D., et al. Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Infect Immun 1997, 65(6):2107-2111.
14. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007, 5(7):540-553.
15. Hallander H.O., Paniagua M., Espinoza F., Askelof P., Corrales E., Ringman M., et al. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 2002, 21(1-2):138-145.
16. Hanlon P., Hanlon L., Marsh V., Byass P., Shenton F., Hassan-King M., et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987, 1(8546):1342-1345.
17. John T. Immunisation against polioviruses in developing countries. Rev Med Virol 1993, (3):149-160.
18. Suharyono, Simanjuntak C., Witham N., Punjabi N., Heppner D.G., Losonsky G., et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992, 340(8821):689-694.
19. Balraj V., John T.J., Thomas M., Mukundan S. Efficacy of oral poliovirus vaccine in rural communities of North Arcot District, India. Int J Epidemiol 1990, 19(3):711-714.
20. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):615-623.